Choi H, Kim K, Han J, Choi H, Jin SH, Lee EK
Beyond glycemic endpoints, GLP-1s are being evaluated for cardiometabolic and neuroprotective roles, expanding their use across specialties (Nauck & Meier, 2020
However, doctors and scientists also noticed the drugs effect on appetite suppression, which has proven highly effective in sustained weight loss
The remaining 5% of prescriptions issued by NHS England have grown by 900% since 2020, far surpassing available primary care resources (1)
2 Over five years of follow-up: 57.7% of GLP-1 users had opioid prescriptions vs 67.7% of non-users 25.5% had fatigue-related diagnostic codes vs 33.6% 47.0% had chronic pain diagnostic codes vs 52.9% There was no significant difference in disability-related codes These differences were statistically significant
They quickly react with other molecules and make a chain reaction, called oxidation